Clinical trial results

Explore the landscape of Clinical trial results in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial results to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes
CompanyDrug

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes

GenFleet Therapeutics (HKG: 2595) announced preliminary clinical data from its Phase Ia dose‑escalation study of investigational GFH276, an oral molecular‑glue Pan‑RAS inhibitor, in patients with pretreated RAS‑mutant solid tumors –…

CStone's Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

CStone’s Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

J&J’s Tecvayli Shows Promising Response Rates in Multiple Myeloma Trial

CompanyDrug

Bristol Myers Squibb’s Breyanzi Shows Promising Results in Three Lymphoma Trials

CompanyDrug

Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial

CompanyDrug

MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study

CompanyDrug

Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT

CompanyDrug

Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers

CompanyDrug

Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors

CompanyDrug

Bristol Myers Squibb’s Krazati Meets Primary Endpoint in Late-Stage Lung Cancer Study

Show More